A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period
NCT05002933
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
570
Enrollment
INDUSTRY
Sponsor class
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:
Insulin glargine 300 U/ml
Sponsor
Sanofi